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Objectives This study sought to compare everolimus-eluting stents (EES) with zotarolimus-eluting
stents (ZES) in patients with acute myocardial infarction (AMI).
Background There is a paucity of data to exclusively evaluate the safety and efﬁcacy of second-
generation drug-eluting stents (DES) in the setting of AMI.
Methods The present study enrolled 3,309 AMI patients treated with ZES (n  1,608) or EES (n 
1,701) in a large-scale, prospective, multicenter registry—KAMIR (Korea Acute Myocardial Infarction
Registry). Propensity score matching was applied to adjust for differences in baseline clinical and
angiographic characteristics, producing a total of 2,646 patients (1,343 receiving ZES, and 1,343 re-
ceiving EES). Target lesion failure (TLF) was deﬁned as the composite of cardiac death, recurrent
nonfatal myocardial infarction, or target lesion revascularization. Major clinical outcomes at 1 year
were compared between the 2 propensity score-matched groups.
Results After propensity score matching, baseline clinical and angiographic characteristics were
similar between the 2 groups. Clinical outcomes of the propensity score-matched patients showed
that, despite similar incidences of recurrent nonfatal myocardial infarction and in-hospital and 1-year
mortality, patients in the EES group had signiﬁcantly lower rates of TLF (6.5% vs. 8.7%, p  0.029)
and probable or deﬁnite stent thrombosis (0.3% vs. 1.6%, p  0.001), compared with those in the
ZES group. Furthermore, there was a numerically lower rate of target lesion revascularization (1.2%
vs. 2.2%, p  0.051) in the EES group than in the ZES group.
Conclusions In this propensity-matched comparison, EES seems to be superior to ZES in reducing
TLF and stent thrombosis in patients with AMI. (J Am Coll Cardiol Intv 2012;5:936–45) © 2012 by
the American College of Cardiology Foundation
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937First-generation drug-eluting stents (DES), including
sirolimus-eluting stents and paclitaxel-eluting stents, have been
demonstrated to be superior to bare-metal stents (BMS) in
reducing the need for repeat revascularization for the treatment
of obstructive coronary artery disease (1). However, concerns
have been raised with regard to the safety of DES, especially in
the acute myocardial infarction (AMI) setting. Some studies
showed that DES had a higher rate of stent thrombosis
compared with BMS even long after the index procedure (2).
ther studies revealed that the polymers of the first-generation
ES were associated with local allergic reactions, inflamma-
ion, and delayed endothelialization, leading to early and late
tent thrombosis (3). Therefore, second-generation DES with
ew stent platforms, polymers, and drugs have been developed
ith the goal to further improve upon the safety profile of
rst-generation DES while maintaining efficacy.
The second-generation DES use modified metal alloys that
nable stent struts to be thinner and have different stent designs
ntended to provide better deliverability and conformability of
he stent to the vessel wall. To date, the safety and efficacy of
econd-generation DES—such as zotarolimus-eluting stent
ZES) (Endeavor Sprint, Medtronic CardioVascular, Santa
osa, California) and everolimus-eluting stent (EES) (Xience
, Abbott Vascular, Santa Clara, California)—has been well-
stablished through comparisons with first-generation DES
4–8). However, the role of the second-generation DES in
MI has not been fully elucidated. Furthermore, no previous
tudy has compared EES with ZES exclusively in patients with
MI. Therefore, the aim of the present study was to evaluate
he safety and efficacy of EES versus ZES in the setting
f AMI in a large-scale, prospective, multicenter regis-
ry—the KAMIR registry (Korea Acute Myocardial In-
arction Registry).
ethods
KAMIR. The design of the KAMIR study has been intro-
uced before (9). In brief, it is a Korean prospective
ulticenter online registry designed to reflect the “real-
orld” practice in a series of Asian patients presenting with
MI in the DES era since November 2005. Online registry
f AMI has been performed at 57 university or community
ospitals, which are high-volume centers with facilities for
rimary percutaneous coronary intervention (PCI) and on-
ite cardiac surgery. Data were collected at each site by a
rained study coordinator with a standardized case report
orm. Standardized definitions of all patient-related vari-
bles and clinical diagnoses were used. The study protocol
as approved by the ethics committee at each participating
nstitution. Patients with AMI, including both ST-segment
levation myocardial infarction (STEMI) and non–ST-
egment elevation myocardial infarction (NSTEMI) were
nrolled. mStudy population. From January 2008 to October 2010, a
otal of 13,726 patients were diagnosed with AMI. In the
resent study, we retrospectively enrolled patients with
MI who received EES (Xience V, Abbott Vascular), or
ES (Endeavor Sprint, Medtronic CardioVascular) im-
lantation and completed 1-year clinical follow-up. The
riteria to exclude the patients were other DES or BMS
mplantation, balloon angioplasty alone, conservative treat-
ent without PCI, contraindication to antithrombotic
gents, known bleeding disor-
ers, infarction related to the
rafted vessel, and estimated life
xpectancy of 12 months.
Therefore, a total of 3,309
ligible AMI patients were fi-
ally enrolled into the present
nalysis. According to the DES
ypes, patients were divided into
groups as follows: ZES group
n  1,608) and EES group (n 
,701). The use percentages of
ES among the centers ranged
rom 7.1% to 58.6% with a me-
ian 21.8% (interquartile range:
3.3% to 33.6%). Loading doses
f aspirin and clopidogrel were
dministered immediately after
atient arrival at the hospital.
he loading/maintenance doses
ere 200 to 300 mg/100 mg q.d.
or aspirin, 300 to 600 mg/75
g q.d. for clopidogrel. All pa-
ients were encouraged to con-
inue dual antiplatelet therapy
ith aspirin and clopidogrel for at
east 12 months.
PCI procedure and medical treat-
ment. Diagnostic angiography
nd PCI were performed through
ither femoral or radial artery
fter administration of unfrac-
ionated heparin (70 to 100
/kg). Patients received unfrac-
ionated heparin to maintain the
ctivated clotting time of250 s
uring the procedure. Stents were deployed after prior
alloon angioplasty, and the use of cilostazol or platelet
lycoprotein (GP) IIb/IIIa receptor blockers was left to the
iscretion of the individual operator. The successful PCI
as defined as the achievement of an angiographic residual
tenosis 30% in the presence of Thrombolysis In Myo-
ardial Infarction blood flow grade 3.
During the in-hospital period, the patients received
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
GP  glycoprotein
IVUS  intravascular
ultrasound
LAD  left anterior
descending artery
LCX  left circumflex
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
RCA  right coronary artery
Re-MI  recurrent
myocardial infarction
STEMI  ST-segment
elevation myocardial
infarction
TLF  target lesion failure
TLR  target lesion
revascularization
TVR  target vessel
revascularization
ZES  zotarolimus-eluting
stent(s)
ZES-R  zotarolimus-eluting
stent-Resoluteedical treatment, including beta-blockers, angiotensin-
Continued in the next column
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938converting enzyme inhibitors or angiotensin II receptor
blockers, calcium channel blockers, and statins. After dis-
charge, the patients were encouraged to continue the same
medications they received in the hospital, except some
intravenous or temporary medications.
Study deﬁnitions and clinical follow-up. The cardiovascular
risk factors and past history records (age, sex, hypertension,
dyslipidemia, smoking, diabetes mellitus, family history of
coronary heart disease, prior myocardial infarction [MI],
chronic heart failure and prior cerebrovascular disease,
peripheral arterial disease) were mainly dependent on pa-
tient self-report, but the final records were left to physician
discretion after he or she had comprehensively considered
the patient self-report and in-hospital examination results.
All deaths were considered cardiac in origin unless a
noncardiac origin was definitely documented. Recurrent
myocardial infarction (Re-MI) was defined as recurrent
symptoms with new ST-segment elevation or re-elevation
of cardiac markers to at least twice the upper limit of
normal. Target lesion revascularization (TLR) was defined
as ischemia-induced PCI of the target lesion due to reste-
nosis or re-occlusion within the stent or in an adjacent 5
mm of the distal or proximal segment. Target vessel
revascularization (TVR) was defined as clinically driven PCI
of the target lesion or any segment of the coronary artery
containing the target lesion. Target lesion failure (TLF) was
defined as the composite of cardiac death, nonfatal Re-MI,
or TLR. Total major adverse cardiac events (MACE)
included total death, nonfatal Re-MI, or TVR. Stent
thrombosis was defined according to the Academic Re-
search Consortium definitions and categorized according to
Table 1. Continued
Variables
ZES
(n  1,608)
EES
(n  1,701)
p
Value
In-hospital medical treatment
Aspirin 1,595 (99.2) 1,687 (99.2) 0.963
Clopidogrel 1,589 (98.8) 1,683 (98.9) 0.736
Glycoprotein IIb/IIIa receptor
blockers
223 (13.9) 224 (13.2) 0.556
Cilostazol 466 (29.0) 495 (29.1) 0.939
Low molecular weight heparin 339 (21.1) 346 (20.3) 0.599
Unfractionated heparin 1,095 (68.1) 1,130 (66.4) 0.308
Beta-blockers 1,389 (86.4) 1,487 (87.4) 0.376
Angiotensin-converting enzyme
inhibitors
1,076 (66.9) 1,159 (68.1) 0.453
Angiotensin II receptor blockers 321 (20.0) 376 (22.1) 0.131
Calcium-channel blockers 94 (5.8) 111 (6.5) 0.418
Statins 1,306 (81.2) 1,389 (81.7) 0.745
Values are mean SD or n (%).
CAD coronary artery disease; EES everolimus-eluting stent(s); LAD left anterior descend-
ing artery; LCX left circumflex;MImyocardial infarction; NYHANewYorkHeart Association
functional class; PCI percutaneous coronary intervention; RCA right coronary artery; TIMI
Thrombolysis In Myocardial Infarction; ZES zotarolimus-eluting stent(s).Table 1. Baseline Characteristics and In-Hospital Medical Treatment
Variables
ZES
(n  1,608)
EES
(n  1,701)
p
Value
Clinical characteristics
Age, yrs 63.85 12.63 62.64 12.22 0.006
Male 1,164 (72.4) 1,243 (73.1) 0.685
History
Hypertension 804 (50.0) 828 (48.7) 0.447
Dyslipidemia 244 (15.2) 255 (15.0) 0.883
Current smoking 720 (45.7) 768 (45.1) 0.829
Diabetes mellitus 461 (28.7) 556 (32.7) 0.012
Family history of CAD 148 (9.2) 151 (8.9) 0.743
Impaired renal function 27 (1.7) 25 (1.5) 0.628
Peptic ulcer 36 (2.2) 38 (2.2) 0.993
Cerebrovascular disease 114 (7.1) 104 (6.1) 0.258
Prior myocardial infarction 81 (5.0) 66 (3.9) 0.106
Prior heart failure (NYHA III/IV) 15 (0.9) 35 (2.1) 0.008
Diagnosis
ST-segment elevation MI 985 (61.3) 1,022 (60.1) 0.490
Primary PCI 903 (91.7) 945 (92.5) 0.512
Non–ST-segment elevation MI 623 (38.7) 679 (39.9) 0.490
Early invasive treatment 492 (79.0) 519 (76.4) 0.272
Killip class 0.579
I 1,139 (70.8) 1,230 (72.3)
II 244 (15.2) 256 (15.0)
III 127 (7.9) 129 (7.6)
IV 98 (6.1) 86 (5.1)
Angiographic and procedural
characteristics
Target lesion 0.787
LAD 785 (48.8) 821 (48.3)
RCA 528 (32.8) 546 (32.1)
LCX 260 (16.2) 291 (17.1)
Left main 35 (2.2) 43 (2.5)
Diseased vessels 0.799
Single 679 (42.2) 704 (41.4)
Double 504 (31.3) 521 (30.6)
Triple 376 (23.4) 421 (24.8)
Left main disease 49 (3.0) 55 (3.2)
Pre-procedure TIMI ﬂow grade 0.144
0 786 (48.9) 803 (47.2)
I 172 (10.6) 207 (12.2)
II 262 (16.3) 245 (14.4)
III 388 (24.1) 446 (26.2)
Stent diameter, mm 3.15 0.43 3.18 0.43 0.039
Stent length, mm 24.10 6.08 22.88 4.97 0.001
Total stents/patient, n 1.52 0.80 1.49 0.80 0.418
Post-procedure TIMI ﬂow grade 0.974
0 7 (0.4) 8 (0.5)
I 6 (0.4) 8 (0.5)
II 10 (0.6) 10 (0.6)
III 1,585 (98.6) 1,675 (98.5)
Use of intravascular ultrasound 363 (22.6) 453 (26.6) 0.007
Use of glycoprotein IIb/IIIa
receptor blockers
312 (19.4) 288 (16.9) 0.065the timing of the event as acute (occurrence within the first
Continued in the next column
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93924 h after the index procedure), subacute (from 24 h to 30
days), and late (from 30 days to 1 year) (10).
Patients were required to visit the outpatient department
of cardiology at the end of the first month and then every 6
months after the PCI procedure as well as whenever
angina-like symptoms occurred. The cumulative incidences
of various MACE during hospital stay and at 1 year were
compared between the 2 groups.
Statistical analysis. Continuous variables were presented as
mean  SD and compared with the Student t test. Cate-
gorical variables were expressed as percentages and com-
pared with the chi-square test or the Fischer exact test,
where indicated. To account for the selection bias of
different stents, we calculated propensity score predicting
probability for receiving different DES in each patient. The
covariates that were adjusted for exposure to DES included
age, sex, Killip class on admission, cardiovascular risk factors
(hypertension, dyslipidemia, smoking, diabetes mellitus,
family history of coronary artery disease), prior MI, chronic
heart failure and prior cerebrovascular disease, moderate to
severe renal dysfunction, diagnosis (STEMI vs. NSTEMI),
target vessel, number of diseased vessels, pre-procedure
Thrombolysis In Myocardial Infarction blood flow grade,
stent diameter, stent length, total stent number/patient,
use of intravascular ultrasound (IVUS), and use of GP
IIb/IIIa receptor blockers in procedure. The C-statistic
for the logistic regression model that was used to calcu-
late the propensity score matching for the 2 groups was
0.684.
Patients receiving EES were then 1-to-1 matched to the
patients receiving ZES on the propensity scores with the
nearest available pair matching method. Subjects were matched
with a caliper width equal to 0.05. The procedure yielded 1,343
Table 2. Continued
Variables
ZES
(n  1,343)
EES
(n  1,343)
p
Value
In-hospital medical treatment
Aspirin 1,335 (99.4) 1,331 (99.1) 0.369
Clopidogrel 1,327 (98.8) 1,328 (98.9) 0.857
Glycoprotein IIb/IIIa receptor
blockers
190 (14.1) 210 (15.6) 0.278
Cilostazol 378 (28.1) 416 (31.0) 0.108
Low molecular weight heparin 286 (21.3) 279 (20.8) 0.740
Unfractionated heparin 894 (66.6) 916 (68.2) 0.365
Beta-blockers 1,179 (87.8) 1,184 (88.2) 0.767
Angiotensin-converting enzyme
inhibitors
865 (64.4) 886 (66.0) 0.395
Angiotensin II receptor blockers 301 (22.4) 298 (22.2) 0.889
Calcium channel blockers 86 (6.4) 89 (6.6) 0.815
Statins 1,147 (85.4) 1,133 (84.4) 0.451
Values are mean SD or n (%).
Abbreviations as in Table 1.Table 2. Baseline Characteristics and In-Hospital Medical Treatment of
Propensity Score-Matched Patients
Variables
ZES
(n  1,343)
EES
(n  1,343)
p
Value
Clinical characteristics
Age, yrs 63.44 12.59 63.64 11.98 0.680
Male 967 (72.0) 976 (72.6) 0.698
History
Hypertension 678 (50.5) 666 (49.6) 0.643
Dyslipidemia 171 (12.9) 188 (14.2) 0.312
Current smoking 607 (46.1) 594 (45.5) 0.703
Diabetes mellitus 384 (28.6) 363 (27.0) 0.366
Family history of CAD 129 (9.6) 116 (8.6) 0.384
Impaired renal function 23 (1.7) 20 (1.5) 0.645
Peptic ulcer 27 (2.0) 26 (1.9) 0.890
Cerebrovascular disease 87 (6.5) 93 (6.9) 0.643
Prior myocardial infarction 45 (3.4) 60 (4.5) 0.135
Prior heart failure (NYHA III/IV) 13 (1.0) 12 (0.9) 0.841
Diagnosis
ST-segment elevation MI 825 (61.4) 833 (62.0) 0.751
Primary PCI 759 (92.0) 780 (93.6) 0.197
Non–ST-segment elevation MI 518 (38.6) 510 (38.0) 0.751
Early invasive treatment 414 (79.9) 395 (77.5) 0.333
Killip class 0.899
I 972 (72.4) 964 (71.8)
II 206 (15.3) 201 (15.0)
III 95 (7.1) 103 (7.7)
IV 70 (5.2) 75 (5.6)
Angiographic and procedural
characteristics
Target lesion 0.949
LAD 647 (48.2) 654 (48.7)
RCA 448 (33.4) 439 (32.7)
LCX 220 (16.4) 225 (16.8)
Left main 28 (2.1) 25 (1.9)
Diseased vessels 0.516
Single 576 (42.9) 557 (41.5)
Double 424 (31.6) 413 (30.8)
Triple 303 (22.6) 336 (25.0)
Left main disease 40 (3.0) 37 (2.8)
Pre-procedure TIMI ﬂow grade 0.280
0 646 (48.1) 641 (47.7)
I 140 (10.4) 157 (11.7)
II 223 (16.6) 192 (14.3)
III 334 (24.9) 353 (26.3)
Stent diameter, mm 3.14 0.43 3.13 0.40 0.393
Stent length, mm 23.68 5.46 24.05 4.56 0.056
Total stents/patient, n 1.50 0.80 1.49 0.79 0.698
Post-procedure TIMI ﬂow grade 0.695
0 6 (0.4) 5 (0.4)
I 5 (0.4) 2 (0.1)
II 9 (0.7) 8 (0.6)
III 1,323 (98.5) 1,328 (98.9)
Use of intravascular ultrasound 298 (22.2) 266 (19.8) 0.130
Use of glycoprotein IIb/IIIa
receptor blockers
250 (18.6) 270 (20.1) 0.329well-matched pairs. After propensity score matching, the
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940baseline covariates were compared between the 2 stent
groups. Continuous variables were compared with the
paired t test, and categorical variables were compared with
hi-square test or Fisher exact test, as appropriate. Various
linical outcomes at 1 year were estimated with the Kaplan-
eier method, and differences between groups were com-
ared with the log-rank test in the propensity score-
atched patients.
The proportional hazard models were used to assess the
djusted hazard ratio comparing the 2 stent types in both
ntire patients and propensity score-matched patients. The
utcomes of both groups were censored at a fixed point of 1
ear (365 days) to avoid any bias caused by different
ollow-up duration.
For all analyses, a 2-sided p  0.05 was considered
statistically significant. All data were processed with SPSS
(version 13.0, SPSS-PC, Inc. Chicago, Illinois).
Results
There was considerable imbalance in baseline clinical and
angiographic characteristics between the patients in the
ZES group versus the EES group, including age, stent
diameter, stent length, the rates of diabetes, prior heart
failure, use of platelet GP IIb/IIIa receptor blockers, and use
of IVUS during procedure (Table 1). However, the in-
hospital medical treatments were similar between the 2
Table 3. Clinical Outcomes of ZES Versus EES Group
Variables
Entir
ZES
(n  1,608) (
In-hospital outcomes
Cardiac death 87 (5.4)
Total death 96 (6.0)
Outcomes at 1 yr
Cardiac death 99 (6.2)
Total death 144 (9.0)
Recurrent MI 28 (1.7)
TLR 34 (2.1)
TVR 46 (2.9)
TLF 152 (9.5)
Total MACE 208 (12.9)
Probable or deﬁnite stent thrombosis 22 (1.4)
Acute 2 (0.1)
Subacute 12 (0.7)
Late 8 (0.5)
1–6 months 1 (0.1)
6–12 months 7 (0.4)
Values are n (%). Target lesion failure (TLF) was defined as the compos
MACEmajor adverse cardiac events; TVR target vessel revascugroups (Table 1). cAfter propensity score matching, the baseline clinical and
angiographic characteristics of the 2 propensity-matched
groups (1,343 pairs, n  2,686 total) were balanced in most
measured characteristics, except that patients in the EES
group tended to receive longer stents compared with those
in the ZES group (24.05  4.56 mm vs. 23.68  5.46 mm,
 0.056) (Table 2).
Clinical outcomes are summarized in Table 3. In the
ntire patient cohort before propensity score matching,
atients in the EES group had significantly lower incidences
f in-hospital cardiac death, total death, and 1-year cardiac
eath than patients in the ZES group. Furthermore, the
ncidences of TLR, TVR, TLF, total MACE, probable or
efinite stent thrombosis, and subacute stent thrombosis
ere also significantly lower in the EES group than in the
ES group.
In the propensity score-matched cohort, the differences of
n-hospital and 1-year mortality were no longer statistically
ignificant. But patients in the EES group still showed
ignificantly lower rates of TLF, total MACE, probable or
efinite stent thrombosis, and subacute stent thrombosis
ompared with those in the ZES group. Furthermore, there
ere numerically lower rates of TLR (p  0.051) and TVR
p 0.056) in the EES group than in the ZES group (Table 3).
Figure 1 shows Kaplan-Meier curves for various clinical
utcomes up to 1 year in the propensity-matched cohort.
igure 2 presents adjusted hazard ratios for various 1-year
ore and After Propensity Score Matching
ents Propensity Score-Matched Patients
S
,701) p Value
ZES
(n  1,343)
EES
(n  1,343) p Value
3.9) 0.045 62 (4.6) 56 (4.2) 0.572
4.1) 0.015 67 (5.0) 59 (4.4) 0.465
4.2) 0.010 71 (5.3) 60 (4.5) 0.324
5.9) 0.001 106 (7.9) 82 (6.1) 0.070
1.4) 0.364 25 (1.9) 20 (1.5) 0.452
1.2) 0.033 29 (2.2) 16 (1.2) 0.051
1.6) 0.018 39 (2.9) 24 (1.8) 0.056
6.1) 0.001 117 (8.7) 87 (6.5) 0.029
8.2) 0.001 161 (12.0) 115 (8.6) 0.003
0.4) 0.001 22 (1.6) 4 (0.3) 0.001
0.1) 0.615 2 (0.1) 0 (0) 0.500
0.1) 0.005 12 (0.9) 1 (0.1) 0.002
0.2) 0.109 8 (0.6) 3 (0.2) 0.131
0.1) 1.000 1 (0.1) 1 (0.1) 1.000
0.1) 0.100 7 (0.5) 2 (0.1) 0.179
rdiac death, recurrent MI and target lesion revascularization (TLR).
n; other abbreviations as in Table 1.s Bef
e Pati
EE
n  1
67 (
70 (
71 (
101 (
23 (
20 (
28 (
103 (
139 (
6 (
1 (
2 (
3 (
1 (
2 (
ite of calinical outcomes associated with EES compared with ZES
EES  everolimus-eluting stent(s); ZES  zotarolimus-eluting stent(s).
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941in the entire patient (Fig. 2A) and propensity score-
matched cohort (Fig. 2B). The use of EES was a statistically
significant predictor of 1-year total death, TLR, TVR,
TLF, total MACE, and probable or definite stent throm-
bosis in the entire patient cohort (Fig. 2A). In the propen-
sity score-matched cohort, the use of EES was an indepen-
dent protective predictor of TLR, TLF, total MACE, and
probable or definite stent thrombosis (Fig. 2B). Figure 3
lists the independent predictors of TLF (Fig. 3A) and
probable or definite stent thrombosis (Fig. 3B).
Discussion
The main finding of this “real-world” propensity score-
matched analysis was that the use of EES was associated
with a reduction in 1-year TLF and probable or definite
stent thrombosis compared with ZES in the setting of
AMI.
Although both ZES (Endeavor Sprint) and EES (Xience V)
are considered second-generation DES, the performances of
these 2 stents have been shown to be different. Some
previous studies suggested that late lumen loss in EES was
low (approximately 0.15 mm) (11,12), whereas it was much
greater in ZES (approximately 0.6 mm) (4,13). However,
there are limited data that directly compare these 2 stents.
Recently, 2 small-scale nonrandomized studies compared
EES with ZES in patients with bifurcation lesions and
reported that the use of EES resulted in superior 1-year
clinical outcomes (14,15). Another registry study evaluated
the relationship between the stent design and periprocedural
MI and showed that the use of EES was associated with less
periprocedural myocardial injury compared with ZES (16).
Although there is a paucity of data directly comparing
EES with ZES (Endeavor Sprint), 1 large-scale random-
ized study was performed to compare the safety and efficacy
of the next-generation ZES Resolute (ZES-R) with EES
(17,18). The RESOLUTE All Comers trial enrolled 2,292
patients undergoing PCI, and it showed that next-
generation ZES-R was noninferior to EES with compara-
ble outcomes both at 1 year and 2 years (17,18). Recently,
an observational study comprising 1,402 patients undergo-
ing PCI was done to evaluate the clinical effectiveness of
ZES-R compared with ZES (Endeavor Sprint), and it
showed that the 1-year adverse event rate (cardiac death,
MI, and clinically driven TLR) for patients who received
ZES-R was 3.7% compared with 6.5% for those who
received ZES (19).
Consistent with the aforementioned studies (14–19), our
study also showed that the unrestricted use of EES com-
pared with ZES was associated with a lower rate of TLF,
which was mainly driven by a reduction in TLR. We
suppose the inferior efficacy profiles of ZES might be
partially attributed to its shorter duration of eluting drugFigure 1. Kaplan-Meier Survival Curves Describing Cumulative
Incidences of Various 1-Year Clinical Outcomes in Propensity
Score-Matched Patientsrelease compared with EES and ZES-R. Both ZES and
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942ZES-R release zotarolimus and have the same cobalt
chromium platform, but the biocompatible polymer of
ZES-R allows for an extended drug release of approximately
6 months compared with the 14-day release with ZES
(Endeavor Sprint) (19).
It should be noted that the present study showed lower
Figure 2. Adjusted Hazard Ratios for Various Clinical Outcomes Associated
Adjusted hazard ratios for various clinical outcomes associated with EES comp
Variables in the multivariable Cox proportional hazard models: stent types (EE
sion, dyslipidemia, smoking, diabetes mellitus, family history of coronary artery
lar disease, moderate-to-severe renal dysfunction, diagnosis (ST-segment eleva
target vessel, number of diseased vessels, pre- and post-procedure Thromboly
stent number/patient, use of intravascular ultrasound, and use of glycoprotein
adverse cardiac events; Re-MI  recurrent myocardial infarction; ST  stent th
target vessel revascularization.event rates compared with some other studies (5,20,21). Wespeculate that the difference between our study and some
previous studies might be due to the different study popu-
lations and follow-up regimens. First, approximately 92% of
STEMI patients received primary PCI, and nearly 80% of
NSTEMI patients received early invasive treatment in the
present study. In addition, optimal medical therapy with
EES Compared With ZES
ith ZES in the entire (A) and propensity score-matched patient cohort (B).
ES), age, sex, Killip class on admission, cardiovascular risk factors (hyperten-
se), prior myocardial infarction, chronic heart failure and prior cerebrovascu-
yocardial infarction vs. non-ST-segment elevation myocardial infarction),
Myocardial Infarction blood ﬂow grade, stent diameter, stent length, total
a receptor blockers in procedure. CI  conﬁdence interval; MACE  major
sis; TLF  target lesion failure; TLR  target lesion revascularization; TVR With
ared w
S vs. Z
disea
tion m
sis In
IIb/III
rombohigh use rates of cardiovascular beneficial medications might have
rction;
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943improved the clinical outcomes of our patients (Tables 1 and 2).
Second, we routinely performed clinical follow-up, but the
angiographic follow-up was not routinely performed in the
present study. Some patients with angiographic in-stent
restenosis might be asymptomatic and could not be found in
the clinical follow-up. And this might be an important
reason for the lower incidence of clinically driven TLR in
the present study.
Although the second-generation DES have been proved
to be safer than the first-generation DES in reducing stent
thrombosis, there is still a paucity of data with regard to the
real-world incidence of late stent thrombosis after implan-
tation of the second-generation DES (8,21). De la Torre
Hernandez et al. (20) evaluated second-generation DES
thrombosis in clinical practice. A total of 4,768 patients
Figure 3. Independent Predictors of TLF and Probable or Definite ST
Independent predictors of TLF (A) and probable or deﬁnite ST (B). GP  glyco
taneous coronary intervention; STEMI  ST-segment elevation myocardial infawere included (2,549 treated with ZES, and 2,219 withEES). The 1-year cumulative incidence of probable or
definite stent thrombosis was 1.3% in the ZES group and
1.4% in the EES group (p  0.800). In the present study,
the incidence of stent thrombosis in the patients treated
with ZES was similar to the results of the previous studies
(20). However, the rate of probable or definite stent
thrombosis in the patients treated with EES was relatively
lower compared with some previous studies, which showed
1-year stent thrombosis ranging from 0.7% to 0.8% (7,22).
But the SPIRIT (Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System) IV study
showed that the rate of probable or definite stent thrombosis
was 0.29% at 1 year in 2,459 EES-treated patients (23).
Furthermore, a meta-analysis from Baber et al. (24) also
suggested that EES was associated with highly significant
in; NSTEMI  non–ST-segment elevation myocardial infarction; PCI  percu-
other abbreviations as in Figure 2.protereductions in stent thrombosis (relative risk: 0.55, 95%
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944confidence interval: 0.38 to 0.78, p 0.001) compared with
ther DES. We suppose that the high use rates of IVUS
24.7%) and GP IIb/IIIa receptor blockers (18.1%) during
he procedure might have effectively reduced stent under-
xpansion, intimal dissection, and stent malapposition,
hich have been proved to be major risk factors for early
nd late stent thrombosis (2,25). Furthermore, the use rate
f additional cilostazol was high (29.0%) in the present
tudy, which might also have a favorable outcome toward
eduction of stent thrombosis (26). The mechanism behind
he lower rate of probable or definite stent thrombosis in
he EES group compared with that in the ZES group
emains unclear. But it was seen that— going by recent
omparative animal study where PCI was performed in
abbit iliac arteries—more rapid re-endothelialization
as observed with EES compared with ZES as assessed
y both a higher degree of morphometric (electron micros-
opy) and functional (CD-31 expression) extent of endo-
helialization (27).
Study limitations. First, stents were assigned by the individ-
al operator, so possibility of operator bias might be
onsidered. Although we used propensity score matching in
he present study to adjust potential bias of stent selection,
ome important variables might have been ignored. How-
ver, this prospective multicenter registry might help com-
lete the picture gained from randomized trials, which
sually have highly selected patients treated in a nonroutine
etting. Second, although all the patients were encouraged
o receive dual antiplatelet therapy with aspirin and clopi-
ogrel for at least 1 year, antiplatelet treatment compliance
as not recorded in the KAMIR database. The early
iscontinuation of dual antiplatelet therapy would probably
e a major determinant of stent thrombosis. Therefore, the
esults of the stent thrombosis in the present study should
e considered cautiously. Also, although all the patients had
aseline quantitative coronary angiography data and were
ncouraged to receive 6-month follow-up angiography,
-month angiographic follow-up was available for only
1.2% of patients. Therefore, we didn’t list quantitative
oronary angiography results in this study.
onclusions
In the present propensity-matched comparison, EES seems
to be superior to ZES in reducing 1-year TLF and stent
thrombosis in patients with AMI. These findings may be
considered hypothesis-generating, and further randomized
studies are warranted to get definite conclusions.
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